Cargando…
Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease
Lafora disease (LD) is a fatal progressive epilepsy essentially caused by loss‐of‐function mutations in the glycogen phosphatase laforin or the ubiquitin E3 ligase malin. Glycogen in LD is hyperphosphorylated and poorly hydrosoluble. It precipitates and accumulates into neurotoxic Lafora bodies (LBs...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494504/ https://www.ncbi.nlm.nih.gov/pubmed/28536304 http://dx.doi.org/10.15252/emmm.201707608 |
_version_ | 1783247687235141632 |
---|---|
author | Nitschke, Felix Sullivan, Mitchell A Wang, Peixiang Zhao, Xiaochu Chown, Erin E Perri, Ami M Israelian, Lori Juana‐López, Lucia Bovolenta, Paola Rodríguez de Córdoba, Santiago Steup, Martin Minassian, Berge A |
author_facet | Nitschke, Felix Sullivan, Mitchell A Wang, Peixiang Zhao, Xiaochu Chown, Erin E Perri, Ami M Israelian, Lori Juana‐López, Lucia Bovolenta, Paola Rodríguez de Córdoba, Santiago Steup, Martin Minassian, Berge A |
author_sort | Nitschke, Felix |
collection | PubMed |
description | Lafora disease (LD) is a fatal progressive epilepsy essentially caused by loss‐of‐function mutations in the glycogen phosphatase laforin or the ubiquitin E3 ligase malin. Glycogen in LD is hyperphosphorylated and poorly hydrosoluble. It precipitates and accumulates into neurotoxic Lafora bodies (LBs). The leading LD hypothesis that hyperphosphorylation causes the insolubility was recently challenged by the observation that phosphatase‐inactive laforin rescues the laforin‐deficient LD mouse model, apparently through correction of a general autophagy impairment. We were for the first time able to quantify brain glycogen phosphate. We also measured glycogen content and chain lengths, LBs, and autophagy markers in several laforin‐ or malin‐deficient mouse lines expressing phosphatase‐inactive laforin. We find that: (i) in laforin‐deficient mice, phosphatase‐inactive laforin corrects glycogen chain lengths, and not hyperphosphorylation, which leads to correction of glycogen amounts and prevention of LBs; (ii) in malin‐deficient mice, phosphatase‐inactive laforin confers no correction; (iii) general impairment of autophagy is not necessary in LD. We conclude that laforin's principle function is to control glycogen chain lengths, in a malin‐dependent fashion, and that loss of this control underlies LD. |
format | Online Article Text |
id | pubmed-5494504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54945042017-07-05 Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease Nitschke, Felix Sullivan, Mitchell A Wang, Peixiang Zhao, Xiaochu Chown, Erin E Perri, Ami M Israelian, Lori Juana‐López, Lucia Bovolenta, Paola Rodríguez de Córdoba, Santiago Steup, Martin Minassian, Berge A EMBO Mol Med Research Articles Lafora disease (LD) is a fatal progressive epilepsy essentially caused by loss‐of‐function mutations in the glycogen phosphatase laforin or the ubiquitin E3 ligase malin. Glycogen in LD is hyperphosphorylated and poorly hydrosoluble. It precipitates and accumulates into neurotoxic Lafora bodies (LBs). The leading LD hypothesis that hyperphosphorylation causes the insolubility was recently challenged by the observation that phosphatase‐inactive laforin rescues the laforin‐deficient LD mouse model, apparently through correction of a general autophagy impairment. We were for the first time able to quantify brain glycogen phosphate. We also measured glycogen content and chain lengths, LBs, and autophagy markers in several laforin‐ or malin‐deficient mouse lines expressing phosphatase‐inactive laforin. We find that: (i) in laforin‐deficient mice, phosphatase‐inactive laforin corrects glycogen chain lengths, and not hyperphosphorylation, which leads to correction of glycogen amounts and prevention of LBs; (ii) in malin‐deficient mice, phosphatase‐inactive laforin confers no correction; (iii) general impairment of autophagy is not necessary in LD. We conclude that laforin's principle function is to control glycogen chain lengths, in a malin‐dependent fashion, and that loss of this control underlies LD. John Wiley and Sons Inc. 2017-05-23 2017-07 /pmc/articles/PMC5494504/ /pubmed/28536304 http://dx.doi.org/10.15252/emmm.201707608 Text en © 2017 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the Creative Commons Attribution 4.0 (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Nitschke, Felix Sullivan, Mitchell A Wang, Peixiang Zhao, Xiaochu Chown, Erin E Perri, Ami M Israelian, Lori Juana‐López, Lucia Bovolenta, Paola Rodríguez de Córdoba, Santiago Steup, Martin Minassian, Berge A Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease |
title | Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease |
title_full | Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease |
title_fullStr | Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease |
title_full_unstemmed | Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease |
title_short | Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease |
title_sort | abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in lafora disease |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494504/ https://www.ncbi.nlm.nih.gov/pubmed/28536304 http://dx.doi.org/10.15252/emmm.201707608 |
work_keys_str_mv | AT nitschkefelix abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT sullivanmitchella abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT wangpeixiang abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT zhaoxiaochu abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT chownerine abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT perriamim abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT israelianlori abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT juanalopezlucia abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT bovolentapaola abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT rodriguezdecordobasantiago abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT steupmartin abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease AT minassianbergea abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease |